Investors who own more than 5% of a class must file a Schedule 13D or 13G. The latest filing for each security since 12/18/2024, newest first.
| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
Traws Pharma, Inc.
13G/A
TRAW · 68232V884
|
0% |
8/14/2026
Event 6/30/2026
|
|||
| Squadron Master Fund LP | 0% | ||||
| Squadron Capital Management LLC | 0% | ||||
| Matthew Sesterhenn | 0% | ||||
| William Blank | 0% | ||||
|
Relmada Therapeutics, Inc.
13G/A
RLMD · 75955J402
|
7.0% |
8/14/2026
Event 6/30/2026
|
|||
| Squadron Master Fund LP | 7.0% | ||||
| Squadron Capital Management LLC | 7.0% | ||||
| Matthew Sesterhenn | 7.0% | ||||
| William Blank | 7.0% | ||||
|
NextCure, Inc.
13G/A
NXTC · 65343E207
|
1.6% |
8/14/2026
Event 6/30/2026
|
|||
| Squadron Master Fund LP | 1.6% | ||||
| Squadron Capital Management LLC | 1.6% | ||||
| Matthew Sesterhenn | 1.6% | ||||
| William Blank | 1.6% | ||||
|
Lipocine Inc.
13G/A
LPCN · 53630X203
|
9.8% |
8/14/2026
Event 6/30/2026
|
|||
| Squadron Master Fund LP | 9.8% | ||||
| Squadron Capital Management LLC | 9.8% | ||||
| Matthew Sesterhenn | 9.8% | ||||
| William Blank | 9.8% | ||||
|
C4 Therapeutics, Inc.
13G/A
CCCC · 12529R107
|
6.9% |
8/14/2026
Event 6/30/2026
|
|||
| Squadron Master Fund LP | 6.9% | ||||
| Squadron Capital Management LLC | 6.9% | ||||
| Matthew Sesterhenn | 6.9% | ||||
| William Blank | 6.9% | ||||
|
Quince Therapeutics, Inc.
13G
QNCX · 22053A305
|
5.6% |
8/4/2026
Event 7/28/2026
|
|||
| Squadron Master Fund LP | 5.6% | ||||
| Squadron Capital Management LLC | 5.6% | ||||
| Matthew Sesterhenn | 5.6% | ||||
| William Blank | 5.6% | ||||
|
InMed Pharmaceuticals Inc.
13G
INM · 457637700
|
9.8% |
5/27/2026
Event 5/19/2026
|
|||
| Squadron Master Fund LP | 9.8% | ||||
| Squadron Capital Management LLC | 9.8% | ||||
| Matthew Sesterhenn | 9.8% | ||||
| William Blank | 9.8% | ||||
|
Spruce Biosciences, Inc.
13G/A
SPRB · 85209E208
|
0.9% |
5/15/2026
Event 3/31/2026
|
|||
| Squadron Master Fund LP | 0.9% | ||||
| Squadron Capital Management LLC | 0.9% | ||||
| Matthew Sesterhenn | 0.9% | ||||
| William Blank | 0.9% | ||||
|
Scynexis Inc
13G
SCYX · 811292200
|
9.6% |
4/8/2026
Event 3/31/2026
|
|||
| Squadron Master Fund LP | 9.6% | ||||
| Squadron Capital Management LLC | 9.6% | ||||
| Matthew Sesterhenn | 9.6% | ||||
| William Blank | 9.6% | ||||
|
Aprea Therapeutics, Inc.
13G
APRE · 03836J102
|
9.9% |
4/7/2026
Event 3/30/2026
|
|||
| Squadron Master Fund LP | 9.9% | ||||
| Squadron Capital Management LLC | 9.9% | ||||
| William Blank | 9.9% | ||||
| Matthew Sesterhenn | 9.9% | ||||
|
Zentalis Pharmaceuticals, Inc.
13G
ZNTL · 98943L107
|
5.1% |
3/3/2026
Event 2/24/2026
|
|||
| Squadron Master Fund LP | 5.1% | ||||
| Squadron Capital Management LLC | 5.1% | ||||
| Matthew Sesterhenn | 5.1% | ||||
| William Blank | 5.1% | ||||
|
Palisade Bio, Inc.
13G/A
PALI · 696389402
|
3.0% |
2/17/2026
Event 12/31/2025
|
|||
| Squadron Master Fund LP | 3.0% | ||||
| Squadron Capital Management LLC | 3.0% | ||||
| Matthew Sesterhenn | 3.0% | ||||
| William Blank | 3.0% | ||||
|
Pasithea Therapeutics Corp.
13G/A
KTTA · 70261F202
|
9.9% |
2/17/2026
Event 12/31/2025
|
|||
| Squadron Master Fund LP | 9.9% | ||||
| Squadron Capital Management LLC | 9.9% | ||||
| Matthew Sesterhenn | 9.9% | ||||
| William Blank | 9.9% | ||||